Expert Discusses How Blockchains Could Impact The Future of Pharmacy

Video

Brian Thornley, the Associate Vice President of Supply Excellence, Innovation and Digital Strategy at Merck, discusses what makes blockchain unique and what it could mean down the road for pharmacies.

Brian Thornley, the Associate Vice President of Supply Excellence, Innovation and Digital Strategy at Merck, discusses what makes blockchain unique and what it could mean down the road for pharmacies.

He addressed the limitations of blockchain, the regulation and legislation that should be considered, and other potential uses for blockchain in health care.

Related Videos
View in microscopic of pathology cross section tissue ductal cell carcinoma or adenocarcinoma diagnosis by pathologist in laboratory | Image Credit: arcyto - stock.adobe.com
A female doctor sits at her desk and talks to a female patient while looking at her mammogram | Image Credit: lordn - stock.adobe.com
Doctor holding a digital tablet with x-ray of brain and skull skeleton. Headache, meningitis and migraine concept - Image credit: Steph photographies | stock.adobe.com
Woman Physician Talking With Her Patient | Image Credit: LStockStudio - stock.adobe.com
A health visitor explaining a senior woman how to take pills - Image credit: Halfpoint | stock.adobe.com
Diabetes patient turn knob on end of insulin pen and dial up correct insulin dose for injection. Scale window on pen syringe showing number of units dose. Medical equipment is easy to self injection - Image credit: Orawan | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Related Content
Infant holding their mother's finger

Study Results Demonstrate Neurodevelopment Comparable Between CHEU, CHUU at 1 Year

December 7th 2023
Article
Pharmacy Focus: Conversations On Reproductive Health - Episode 2

Pharmacy Focus: Conversations On Reproductive Health - Episode 2

November 29th 2023
Podcast
Adding Pembrolizumab to Chemotherapy Increased Pathological Complete Response, Improved Residual Cancer Burden in Early-Stage, High-Risk ER+/HER2- Breast Cancer

Adding Pembrolizumab to Chemotherapy Increased Pathological Complete Response, Improved Residual Cancer Burden in Early-Stage, High-Risk ER+/HER2- Breast Cancer

December 7th 2023
Article
Independent Rx Forum: NCPA Priorities, Legislative Updates for Independent Pharmacies

Independent Rx Forum: NCPA Priorities, Legislative Updates for Independent Pharmacies

November 28th 2023
Podcast
Pausing Endocrine Therapy for Pregnancy Did Not Increase Risk of Recurrence for Those With HR+ Breast Cancer

Pausing Endocrine Therapy for Pregnancy Did Not Increase Risk of Recurrence for Those With HR+ Breast Cancer

December 7th 2023
Article
Study: Patients With PD-L1-Positive, High-Risk, ER+/HER2- Breast Cancer Can Achieve Substantial Complete Response Rates With Addition of Nivolumab

Study: Patients With PD-L1-Positive, High-Risk, ER+/HER2- Breast Cancer Can Achieve Substantial Complete Response Rates With Addition of Nivolumab

December 6th 2023
Article
© 2023 MJH Life Sciences

All rights reserved.